The July 23–24 PCAC docket contains seven peptides. Four of them — BPC-157, TB-500, MOTS-c, and KPV — are scheduled for day one; three — Emideltide (DSIP), Epitalon, and Semax — for day two. Three of the seven are already woven into the Limitless protocol library: BPC-157 and TB-500 anchor the recovery protocol, and MOTS-c sits in the standing metabolic stack under transparent informed consent about its evidence tier.
That leaves four docketed peptides Limitless does not currently prescribe. One of them — Emideltide / DSIP — holds no active interest for us and is not discussed further here. The other three are worth a real answer, because patients are already asking about them: KPV, Semax, and Epitalon. Each is plausible enough to deserve a roadmap and weak enough, in its current evidence state, to deserve caution. This brief is that roadmap.
First principle: a docket vote is a permission, not a recommendation.
It is worth being precise about what a favorable July vote would and would not do. If the committee recommends a peptide for inclusion on the 503A bulk drug substances list, and FDA rulemaking eventually follows, then licensed compounding pharmacies may legally prepare it against a patient-specific prescription. That is a regulatory permission. It is not a statement that the molecule works, that the dose is known, or that any given patient should take it.
Limitless adds a molecule to the menu when the evidence clears our bar — not when the FDA makes the molecule available. Those are two different events, and conflating them is exactly the error the peptide market made in 2024 and 2025. Every candidate below is measured against the same gate.
- A 503A partner can formulate it to documented stability and per-lot Certificate of Analysis standards.
- A defined indication — a specific patient and a specific problem — not a general "optimization" claim.
- A defined endpoint — something measurable that tells us within a set window whether it is working, so the trial has an exit.
- An honest evidence tier, disclosed to the patient in writing: what the human data does and does not show.
- Written informed consent that names the uncertainty plainly. If we cannot write that consent without overclaiming, the molecule does not go on the menu.
KPV — the closest to a yes.
KPV (Lys-Pro-Val)
KPV is the C-terminal tripeptide of α-melanocyte-stimulating hormone. It is the strongest of the three candidates here, and the only one with a credible near-term path onto the Limitless menu. The mechanism is unusually clean for a peptide: KPV is taken up directly by intestinal epithelial cells through the PepT1 transporter and, once inside, dampens NF-κB–driven inflammatory signaling. In murine colitis models the anti-inflammatory effect has been reproduced consistently across more than fifteen years of work.
The gap is equally clean: there is not a single completed, published human randomized controlled trial of KPV for any indication. The mechanism is attractive and the animal data is coherent, but coherence in mice is a hypothesis, not a result.
Semax — possible, but narrow.
Semax (a synthetic ACTH 4–10 analog)
Semax is a heptapeptide developed in Russia, where it has been in clinical use for decades for ischemic stroke and cognitive indications and is on the Russian essential-medicines list. Its proposed mechanism — modulation of BDNF and the neurotrophin system, with downstream effects on attention and neuroprotection — is biologically reasonable, and the Russian clinical literature is genuinely substantial.
The problem for a US physician is the shape of that literature. It is overwhelmingly single-region, much of it is not designed or reported to the standard a Western regulator or a careful clinician expects, and independent multi-site replication outside Russia is thin to absent. "Used for decades in one country" is a real data point. It is not the same data point as a well-powered, well-controlled, independently replicated trial.
Epitalon — not on the current evidence.
Epitalon (Ala-Glu-Asp-Gly)
Epitalon is a synthetic tetrapeptide modeled on a pineal-gland peptide preparation. It is the most aggressively marketed of the three — sold online with telomerase-activation and lifespan-extension claims — and it has the weakest evidence-to-claim ratio of anything on the July docket. The supporting research traces almost entirely to a single St. Petersburg research group, spanning rodent lifespan experiments and small human cohorts. It has not been independently replicated at scale, and the human longevity endpoints that the marketing implies simply do not exist in a form a physician can responsibly cite.
This is the cleanest example of why a docket vote is not a recommendation. Epitalon could be voted onto the 503A list and still not belong on a serious clinic's menu — because legal availability does not manufacture human evidence. Our posture is research-watch only: we will read the dossier the committee evaluates, and we will not prescribe Epitalon on the strength of telomere marketing.
The second wave — five more peptides, early 2027.
The April 2026 FDA notice that scheduled the July meeting also committed the agency to a second PCAC meeting before the end of February 2027. In May 2026 the FDA named the five peptides that meeting will review: GHK-Cu, Melanotan II, Cathelicidin (LL-37), Dihexa, and PEG-MGF. None is on the Limitless menu today. They are a useful stress-test of the menu-addition gate, because they span the full range — one credible candidate, two research curiosities, and two we would decline regardless of how the committee votes.
The same five-part gate applies without modification. A second-meeting "yes" is the same kind of permission a July "yes" is — and the same distance from a recommendation.
GHK-Cu — the credible one.
GHK-Cu (copper tripeptide · Gly-His-Lys-Cu)
GHK-Cu is a naturally occurring copper-binding tripeptide whose plasma level declines with age. It has the most substantial evidence base of the five second-wave peptides — but almost all of that evidence is topical. Decades of dermatology work support GHK-Cu applied to skin for collagen synthesis, wound remodeling, and anti-inflammatory signaling. As a cosmetic and wound-care ingredient it is well characterized and well tolerated.
The gap is the route. A favorable PCAC vote would concern compounded GHK-Cu, and the controlled evidence for systemic or injected GHK-Cu — as opposed to topical — is thin. The molecule is plausible; the delivery question is unresolved. That is exactly the distinction the marketing collapses and the gate does not.
Melanotan II — a clear no.
Melanotan II (synthetic melanocortin agonist)
Melanotan II is a non-selective melanocortin-receptor agonist marketed — almost entirely through the grey market — as a "tanning peptide." It does darken skin. It also carries a safety profile a careful clinic does not accept: nausea, blood-pressure effects, spontaneous erection, and, most seriously, melanocyte effects that complicate the surveillance of moles and pigmented lesions. Case reports describe new or changing melanocytic lesions in users.
This is the second wave's Epitalon — except the problem is not absent evidence, it is present risk. A favorable committee vote would change Melanotan II's legal status. It would not change the fact that a peptide which interferes with melanoma surveillance does not belong on a serious clinic's menu.
Cathelicidin (LL-37) — research-watch only.
Cathelicidin / LL-37 (human host-defense peptide)
LL-37 is the active fragment of the body's own cathelicidin antimicrobial peptide — genuinely interesting biology, with roles in antimicrobial defense and wound healing. But it is immunologically double-edged: LL-37 is also implicated in the pathology of several autoimmune and inflammatory skin conditions, including psoriasis and rosacea, where excess LL-37 activity is part of the problem rather than the solution.
Controlled human data for LL-37 as a compounded therapeutic is minimal. A molecule that is protective in one context and pathogenic in another demands completed human trials before a clinic can write honest informed consent for it. We will read the dossier; we will not prescribe on mechanism.
Dihexa — research-watch only.
Dihexa (angiotensin IV–derived oligopeptide)
Dihexa is a small synthetic peptide derived from angiotensin IV, studied preclinically for a striking pro-synaptogenic effect through the hepatocyte growth factor / c-Met pathway. The animal cognition data has generated real interest — and real marketing. What does not exist is human clinical trial data of any size.
A potent activator of a growth-factor pathway, with no human safety record, is precisely the molecule the menu-addition gate is built to hold back. Dihexa is a research story worth following, not a prescription. It is discussed further in our cognitive peptide review.
PEG-MGF — a clear no.
PEG-MGF (pegylated mechano growth factor)
PEG-MGF is a pegylated splice variant of IGF-1, marketed almost exclusively to bodybuilders for muscle growth and repair. It pairs two problems. First, credible human clinical trial data is essentially absent — this is a grey-market performance product, not a studied therapeutic. Second, the mechanism is direct activation of the IGF-1 growth axis, where uncontrolled stimulation carries real theoretical oncologic concern.
The Limitless GH-axis posture is deliberately conservative — tesamorelin first, because it works through the body's own regulated GHRH signaling. A pegylated IGF-1 variant with no trial base is the opposite of that philosophy.
The bottom line.
If you are a Limitless patient watching the July docket, here is the short version. KPV is the one to actually watch — a favorable vote opens a real, structured path to a defined GI pilot. Semax is possible but narrow, and would only ever appear as a documented, patient-specific exception, not a menu item. Epitalon is not coming to the menu on the current evidence, regardless of how the committee votes — and you should be skeptical of any clinic that adds it the week the vote clears.
The second wave is simpler to summarize. GHK-Cu is the one credible candidate — and even there, the topical-versus-injectable evidence gap has to close first. LL-37 and Dihexa are research-watch: interesting biology, no human trial base. Melanotan II and PEG-MGF are firm no's on safety and evidence grounds, and no committee vote changes that.
None of this is in suspense for your care. Your protocol is built from FDA-approved molecules and 503A-compounded peptides with credible dossiers. The peptides in this brief are roadmap questions, not gaps. We will update this page within seven days of the July 24 vote with the actual outcomes and any change to the posture above.